24th Oct 2013 15:48
LONDON (Alliance News) - ValiRx PLC Thursday said its anti-cancer treatment drug VAL201 has passed the first stage of testing as is expected to advance to a Phase 2 Study.
Earlier this month the firm conducted a trial on prostate cancer patients through a first in-man study.
A first in-man study is a clinical trial where a medical procedure, previously developed and assessed through in vitro or animal testing, or through mathematical modelling is tested on human subjects for the first time.
Phase 2 aims to establish the efficacy of the drug, usually against a placebo.
The stock closed 0.661 pence Thursday, up 0.071 pence or 12.0%.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
ValiRx